Drug Profile

Pirenzepine - AC Immune

Alternative Names: ACI-91; PSY-130; PSY-130/131; PSY-131

Latest Information Update: 15 Jan 2014

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ProteoSys
Developer AC Immune
Class Antidementias; Antiulcers; Benzodiazepinones; Gastric antisecretories; Piperazines; Pyridones; Small molecules
Mechanism of Action BACE1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Alzheimer's disease

Most Recent Events

31 Jan 2013 Discontinued - Phase-II for Alzheimer's disease in Germany and Austria (PO)
13 Jun 2011 ACI 91 is still in phase II trials for Alzheimer's disease
31 Dec 2008 Phase-II clinical trials in Alzheimer's disease in Germany and Austria (PO)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com